Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

191
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
191
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

332
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
332
Overview of Lipid Metabolism01:24

Overview of Lipid Metabolism

1.7K
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
1.7K
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

674
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
674
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

184
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
184
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

212
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
212

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multi-mode interferometry for measuring the depth of deep silicon-etched microstructures.

Optics express·2026
Same author

Comprehensive analysis of pathogenic mechanisms of Enterobacter cancerogenus ECL9 in silkworms.

Developmental and comparative immunology·2026
Same author

Gα<sub>q</sub> Is a Heterotrimeric G-Protein Subunit That Directs the Selectivity of PPARγ-Induced Gene Pathways Toward Energy-Related Processes Rather than Adiposity.

Metabolites·2026
Same author

Life course shaping of brain ageing: the SHARE blood biomarker study.

medRxiv : the preprint server for health sciences·2026
Same author

Specific and quantitative assay for duck variant orthoreovirus utilizing the loop-mediated isothermal amplification technique.

Journal of immunological methods·2026
Same author

Publisher Correction: GLP-1R-GIPR-PPARα/γ/δ quintuple agonism corrects obesity and diabetes in mice.

Nature·2026

Related Experiment Video

Updated: Jul 11, 2025

Experimental Approach to Examine Leptin Signaling in the Carotid Bodies and its Effects on Control of Breathing
05:45

Experimental Approach to Examine Leptin Signaling in the Carotid Bodies and its Effects on Control of Breathing

Published on: October 25, 2019

6.0K

Leptin Reduction as a Required Component for Weight Loss.

Shangang Zhao1,2,3, Na Li1,4, Wei Xiong5

  • 1Touchstone Diabetes Center, The University of Texas Southwestern Medical Center, Dallas, TX.

Diabetes
|November 7, 2023
PubMed
Summary
This summary is machine-generated.

Reducing leptin levels, a key hormone, is crucial for significant weight loss and improved metabolic health. This study demonstrates that partial leptin reduction enhances the effects of obesity treatments like FGF21 and liraglutide.

More Related Videos

Assessment of the Metabolic Effects of Isocaloric 2:1 Intermittent Fasting in Mice
08:06

Assessment of the Metabolic Effects of Isocaloric 2:1 Intermittent Fasting in Mice

Published on: November 27, 2019

9.0K
Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
11:06

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

2.0K

Related Experiment Videos

Last Updated: Jul 11, 2025

Experimental Approach to Examine Leptin Signaling in the Carotid Bodies and its Effects on Control of Breathing
05:45

Experimental Approach to Examine Leptin Signaling in the Carotid Bodies and its Effects on Control of Breathing

Published on: October 25, 2019

6.0K
Assessment of the Metabolic Effects of Isocaloric 2:1 Intermittent Fasting in Mice
08:06

Assessment of the Metabolic Effects of Isocaloric 2:1 Intermittent Fasting in Mice

Published on: November 27, 2019

9.0K
Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
11:06

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

2.0K

Area of Science:

  • Metabolic research
  • Endocrinology
  • Obesity research

Background:

  • The interplay between leptin reduction and weight loss is complex and requires further investigation.
  • Leptin, a hormone regulating appetite and metabolism, is often reduced following weight loss, but the causal relationship is unclear.

Purpose of the Study:

  • To investigate the role of leptin reduction in mediating the metabolic benefits of FGF21 and glucagon-like peptide 1 receptor (GLP-1R) agonists.
  • To explore whether partial leptin reduction is a viable therapeutic strategy for obesity and associated insulin resistance.

Main Methods:

  • Administered FGF21 and liraglutide (a GLP-1R agonist) to diet-induced obese mice.
  • Utilized transgenic models to maintain leptin levels and leptin-neutralizing antibodies to manipulate leptin concentrations.
  • Assessed weight loss, glucose tolerance, and leptin sensitivity in hypothalamic neurons.

Main Results:

  • FGF21 and liraglutide treatments rapidly reduced leptin levels, contributing to their metabolic benefits.
  • Enhanced leptin reduction, via antibodies, synergistically increased weight loss and improved glucose tolerance.
  • Leptin reduction enhanced leptin sensitivity in hypothalamic neurons, suggesting a key mechanism.
  • Cessation of treatment led to weight regain and increased leptin, which was attenuated by leptin neutralization.

Conclusions:

  • Leptin reduction is a necessary prerequisite for substantial weight loss and improved metabolic health.
  • Partial leptin reduction is a promising therapeutic strategy for managing obesity and insulin resistance.